Esperion Therapeutics Price Target Maintained With a $4.00/Share by Citizens Capital Markets

Dow JonesMar 5 10:14 ET

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsMar 5 01:31 ET

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsMar 4 15:31 ET

Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Cuts Target Price to $5

Moomoo NewsMar 4 14:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaMar 4 10:57 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsMar 3 10:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaFeb 11 06:53 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsFeb 11 06:33 ET

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Cuts Target Price to $4

Moomoo NewsFeb 11 00:32 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsJan 23 09:32 ET

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16

Moomoo NewsJan 23 08:01 ET

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating, Maintains Target Price $2.05

Moomoo NewsJan 16 06:32 ET

Esperion Therapeutics Analyst Ratings

BenzingaJan 10 07:15 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsJan 10 06:31 ET

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating, Maintains Target Price $2.05

Moomoo NewsJan 6 06:34 ET

Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4

Moomoo NewsDec 18, 2024 01:31 ET

Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8

Moomoo NewsDec 17, 2024 17:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaDec 17, 2024 08:41 ET

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

MT NewswiresDec 17, 2024 07:37 ET

Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsDec 13, 2024 13:31 ET